- Price
- $2.51
- Day
- +2.87%
- Mkt Cap
- $66.73M
- 52W Range
- $1.09 – $2.60
- Volume
- 493.7K
- Beta
- 0.94
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.
Read full article
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity
Read full article